Work

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Year: 2008

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.832.832

Authors: Irene M. Ghobrial, Jeffrey Matous, Swaminathan Padmanabhan, Ashraf Badros, Robert Schlossman, Stacey Chuma, Renee Leduc1, Marybeth Nelson, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, Steven P. Treon, Kenneth C. Anderson, Paul Richardson

Institutions: Dana-Farber Cancer Institute, Rocky Mountain Cancer Centers, Roswell Park Comprehensive Cancer Center, University of Maryland, Baltimore

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593556949

FWCI: 0.277

Cites:

Cited by: 8

Related to: 10